Barclays’s CalciMedica CALC Stock Holding History

Barclays’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282	Buy	+55	New	+$195	﹤0.01%	5070
2025 Q4	–	Sell	-11	Closed	-$175	–	5281
2025 Q3	$175	Buy	+11	New	+$158	﹤0.01%	5247

Other funds holding CALC

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

LGM

L1 Global Manager Melbourne $142M AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's CALC Position: Q2 2026 in Review

Barclays opened a new position in CalciMedica (CALC) in Q2 2026: 55 shares worth $282. The stake represents ﹤0.01% of the portfolio and ranks #5070 among its holdings. This is a return to the name: Barclays previously reported a position in CALC as recently as Q3 2025.

Barclays first reported a position in CALC in Q3 2025 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold CALC as of Q2 2026.

Barclays held 55 shares of CalciMedica worth $282 as of Q2 2026.
CalciMedica was a new Barclays position in Q2 2026.
CalciMedica made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5070 holding.
Barclays first reported a position in CalciMedica in Q3 2025 and has held it in 2 quarters since.
31 funds tracked by Wall St. Rank held CalciMedica as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.